CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? - Authors' reply

Lancet Oncol. 2022 Jan;23(1):e14-e15. doi: 10.1016/S1470-2045(21)00722-1.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Humans
  • Immunotherapy / adverse effects
  • Mesothelioma* / drug therapy
  • Mesothelioma, Malignant*